Microbiota Transfer Therapy Could Help Children With Autism

Share this content:
Microbiota Transfer Therapy Could Help Children With Autism
Microbiota Transfer Therapy Could Help Children With Autism

FRIDAY, Jan. 27, 2017 (HealthDay News) -- A new approach to alter the gut microbiome and virome may be an effective treatment for children with autism spectrum disorder (ASD), according to research published online Jan. 23 in Microbiome.

The researchers studied the impact of microbiota transfer therapy on gut microbiota composition and gastrointestinal and ASD symptoms of 18 ASD-diagnosed children. The program consisted of two weeks of antibiotic treatment, a bowel cleanse, and then an extended fecal microbiota transplant using a high initial dose followed by daily and lower maintenance doses for seven to eight weeks.

After the procedure, the children experienced a 25 percent reduction in symptoms related to language, social interaction, and repetitive behaviors, study author James Adams, Ph.D., a professor and autism researcher at Arizona State University in Tempe, told HealthDay. The children also became less hyperactive, irritable, and lethargic. Five weeks into the study, the children had experienced an average 80 percent reduction in the gastrointestinal symptoms most had experienced for years.

"This exploratory, extended-duration treatment protocol thus appears to be a promising approach to alter the gut microbiome and virome and improve gastrointestinal and behavioral symptoms of ASD," the authors write. "Improvements in gastrointestinal symptoms, ASD symptoms, and the microbiome all persisted for at least eight weeks after treatment ended, suggesting a long-term impact."

Several authors disclosed patents related to the use of fecal microbiota transplant and/or probiotics for various conditions, including autism.

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease


Sign up for myCME e-newsletters


More in Home

FDA OKs Lynparza to Treat Breast Cancer With BRCA Mutation

FDA OKs Lynparza to Treat Breast Cancer With ...

PARP inhibitor therapy already approved to treat BRCA-mutated ovarian cancer

Ceramide-Infused Skin Barrier Cuts Stoma-Related Costs

Ceramide-Infused Skin Barrier Cuts Stoma-Related Costs

Use of ceramide-infused barrier tied to lower stoma-related care costs, improved patient satisfaction

Non-Ventilator Hospital-Acquired Pneumonia Risk Affects All Ages

Non-Ventilator Hospital-Acquired Pneumonia Risk Affects All Ages

Non-vent-associated HAP risk occurs in all hospital units; risk extends even to low-risk/younger patients

is free, fast, and customized just for you!

Already a member?

Sign In Now »